242 results
Keyword azacitidine Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Azacitidine Accord
azacitidine, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Date of authorisation: 13/02/2020,
, Authorised, Last updated: 21/02/2020
Azacitidine Accord … Azacitidine Accord Myelodysplastic Syndromes Leukemia … Azacitidine Accord azacitidine azacitidine … -
List item
Human medicine European public assessment report (EPAR): Azacitidine Celgene
azacitidine, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Date of authorisation: 02/08/2019, Authorised, Last updated: 14/08/2019Azacitidine Celgene … Azacitidine Celgene Myelodysplastic … Azacitidine Celgene azacitidine azacitidine … -
List item
Human medicine European public assessment report (EPAR): Azacitidine Mylan
azacitidine, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Date of authorisation: 27/03/2020,, Authorised, Last updated: 06/04/2020
Authorised azacitidine Overview Azacitidine Mylan is used for the treatment … cells called myeloid cells). Azacitidine Mylan is used in patients … cells called monocytes). Azacitidine Mylan is used when the bone … -
List item
Human medicine European public assessment report (EPAR): Azacitidine betapharm
azacitidine, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Date of authorisation: 24/03/2020,, Authorised, Last updated: 01/04/2020
Azacitidine betapharm … Azacitidine betapharm Myelodysplastic … Azacitidine betapharm azacitidine azacitidine … -
List item
Human medicine European public assessment report (EPAR): Vidaza
azacitidine, Myelodysplastic Syndromes
Date of authorisation: 17/12/2008,
, Revision: 18, Authorised, Last updated: 11/04/2019
azacitidine … Vidaza azacitidine azacitidine … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Vidaza, azacitidine
Decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology, PIP number: EMEA-001272-PIP02-13-M01, decision date: 02/10/2015, Last updated: 23/11/2015, compliance check: Xpaediatric investigation plan for azacitidine (Vidaza), (EMEA-001272-PIP02-13-M01 … paediatric investigation plan for azacitidine (Vidaza), (EMEA-001272-PIP02-13-M01 … paediatric investigation plan for azacitidine (Vidaza), (EMEA-001272-PIP02-13-M01 … -
List item
Orphan designation: azacitidine for: Treatment of acute myeloid leukaemia
Date of first decision: 29/11/2007, Expired, Last updated: 20/02/2019Ltd, United Kingdom, for azacitidine for the treatment of acute … Kingdom, in October 2008. Azacitidine in treatment of acute myeloid … orphan drug designation. Azacitidine could be of potential significant … -
List item
Orphan designation: azacitidine for: Treatment of myelodysplastic syndromes
Date of first decision: 06/02/2002, Expired, Last updated: 20/02/2019Limited, United Kingdom, for azacitidine for the treatment of myelodysplastic … Kingdom, in October 2008. Azacitidine in treatment of myelodysplastic … medicine expected to work? Azacitidine is an analogue of cytidine … -
List item
Orphan designation: azacitidine for: Treatment of nasopharyngeal carcinoma
Date of first decision: 11/11/2015, Withdrawn, Last updated: 08/02/2017opinion on orphan designation Azacitidine for the treatment of nasopharyngeal … opinion on orphan designation Azacitidine for the treatment of nasopharyngeal … Limited, United Kingdom, for azacitidine for the treatment of nasopharyngeal …